E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)

The Evidence Based Rheumatology Podcast

Content provided by Michael Putman. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Michael Putman or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

5y ago 10:48

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 25, 2022 17:24 (2+ y ago). Last successful fetch was on November 05, 2021 00:25 (3y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).

83 episodes

#Biology #Environment #Fitness #Michael Putman #Medicine #Science